Cassava Sciences, Inc.
Index- P/E- EPS (ttm)-1.90 Insider Own2.70% Shs Outstand40.78M Perf Week-7.00%
Market Cap998.43M Forward P/E- EPS next Y-2.77 Insider Trans8.64% Shs Float39.45M Perf Month-3.51%
Income-76.20M PEG- EPS next Q-0.56 Inst Own25.50% Short Float / Ratio26.51% / 8.07 Perf Quarter-24.53%
Sales- P/S- EPS this Y-130.80% Inst Trans5.38% Short Interest10.46M Perf Half Y-47.09%
Book/sh5.58 P/B4.33 EPS next Y25.60% ROA-33.40% Target Price84.00 Perf Year-40.48%
Cash/sh4.86 P/C4.97 EPS next 5Y- ROE-34.60% 52W Range13.84 - 51.59 Perf YTD-19.06%
Dividend- P/FCF- EPS past 5Y-0.80% ROI- 52W High-53.65% Beta-0.09
Dividend %- Quick Ratio29.90 Sales past 5Y- Gross Margin- 52W Low72.76% ATR1.35
Employees26 Current Ratio29.90 Sales Q/Q- Oper. Margin- RSI (14)37.66 Volatility5.09% 5.24%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.30% Profit Margin- Rel Volume0.19 Prev Close24.14
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.30M Price23.91
Recom2.30 SMA20-5.53% SMA50-13.20% SMA200-20.71% Volume198,651 Change-0.95%
Nov-16-22Downgrade B. Riley Securities Buy → Neutral $44
Jul-15-21Downgrade Cantor Fitzgerald Overweight → Neutral $100
Jul-07-21Reiterated Maxim Group Buy $80 → $190
Apr-27-21Initiated B. Riley Securities Buy $78
Feb-16-21Reiterated H.C. Wainwright Buy $20 → $66
Oct-23-20Initiated Cantor Fitzgerald Overweight $24
Sep-23-20Upgrade H.C. Wainwright Neutral → Buy $20
May-18-20Downgrade H.C. Wainwright Buy → Neutral
May-15-20Downgrade Maxim Group Buy → Hold
Jan-10-20Reiterated Maxim Group Buy $3 → $12
Mar-09-23 09:45AM
Mar-04-23 07:20AM
Mar-03-23 07:07AM
Feb-28-23 09:15AM
Feb-24-23 01:29PM
09:15AM Loading…
Feb-08-23 09:15AM
Feb-01-23 08:55AM
Jan-25-23 08:27PM
Jan-24-23 04:06PM
Jan-18-23 10:35AM
Jan-12-23 09:40AM
Jan-03-23 09:16AM
Dec-20-22 09:15AM
09:15AM Loading…
Dec-06-22 09:15AM
Nov-22-22 12:30PM
Nov-18-22 01:30PM
Nov-16-22 10:43AM
Nov-15-22 10:00AM
Nov-14-22 03:54PM
Nov-07-22 09:00AM
Nov-04-22 10:49AM
Nov-03-22 09:15AM
Nov-01-22 02:21PM
Oct-31-22 05:50PM
Oct-27-22 09:15AM
Oct-25-22 05:50PM
05:50PM Loading…
Oct-17-22 05:50PM
Oct-13-22 09:15AM
Oct-11-22 06:00PM
Oct-05-22 06:15AM
Sep-30-22 10:35AM
Sep-29-22 06:15PM
Sep-27-22 01:11PM
Sep-23-22 04:11PM
Sep-16-22 06:15PM
Sep-09-22 12:08PM
Sep-08-22 09:15AM
Sep-05-22 08:01PM
Aug-18-22 01:06PM
Aug-17-22 01:40PM
Aug-16-22 06:09PM
Aug-03-22 09:15AM
Jul-29-22 01:29PM
Jul-27-22 02:58PM
Jul-26-22 06:15PM
Jul-24-22 10:00AM
Jun-24-22 06:15PM
Jun-16-22 06:15PM
May-25-22 11:32AM
May-05-22 09:00AM
May-04-22 08:48AM
Apr-29-22 02:40PM
Apr-28-22 05:50PM
Apr-26-22 03:03PM
Apr-25-22 03:11PM
Apr-19-22 03:17PM
Apr-15-22 09:30AM
Apr-14-22 07:14PM
Apr-11-22 05:04PM
Apr-08-22 08:59AM
Apr-07-22 05:29PM
Apr-06-22 06:11PM
Apr-04-22 06:00PM
Apr-01-22 11:37AM
Mar-30-22 06:18PM
Mar-25-22 06:00PM
Mar-18-22 05:50PM
Mar-15-22 01:33PM
Mar-10-22 06:00PM
Mar-04-22 05:50PM
Mar-03-22 04:45PM
Mar-01-22 04:41PM
Feb-28-22 04:03PM
Feb-25-22 05:50PM
Feb-18-22 03:01PM
Feb-17-22 01:35PM
Feb-15-22 05:50PM
Feb-11-22 10:53AM
Feb-10-22 04:07PM
Feb-08-22 05:50PM
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O DONNELL MICHAEL JDirectorMar 07Option Exercise18.137,142129,48412,012Mar 08 04:12 PM
Barry RichardDirectorMar 07Buy25.7677,2761,990,630275,000Mar 08 04:07 PM
Barry RichardDirectorMar 06Buy26.1311,565302,193197,724Mar 08 04:07 PM
FRIEDMANN NADAVChief Medical OfficerOct 03Option Exercise0.959,3768,90779,910Oct 03 06:01 PM
ROBERTSON SANFORDDirectorSep 08Option Exercise23.592,80266,0991,027,567Sep 12 04:00 PM
Barry RichardDirectorAug 23Buy23.7936,159860,223186,159Aug 25 04:20 PM
Kupiec James WilliamChief Clinical Dev. OfficerAug 23Buy24.442,50061,1002,500Aug 24 04:02 PM
ROBERTSON SANFORDDirectorAug 12Buy20.69100,0002,069,0001,024,765Aug 16 04:24 PM
Schoen EricChief Financial OfficerAug 12Buy19.952,50049,87519,800Aug 16 04:28 PM
BARBIER REMIPresident and CEOJun 06Option Exercise23.3865,3681,528,304822,437Jun 07 06:24 PM
FRIEDMANN NADAVChief Medical OfficerMay 27Option Exercise23.3828,014654,96795,103May 31 04:20 PM
BARBIER REMIPresident and CEOApr 25Option Exercise2.4049,460118,703376,112Apr 25 06:29 PM
GUSSIN ROBERT ZDirectorMar 29Option Exercise21.537,470160,85612,434Mar 29 07:20 PM